JP6737533B2 - スピロ環式化合物 - Google Patents

スピロ環式化合物 Download PDF

Info

Publication number
JP6737533B2
JP6737533B2 JP2017552060A JP2017552060A JP6737533B2 JP 6737533 B2 JP6737533 B2 JP 6737533B2 JP 2017552060 A JP2017552060 A JP 2017552060A JP 2017552060 A JP2017552060 A JP 2017552060A JP 6737533 B2 JP6737533 B2 JP 6737533B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
diazaspiro
mmol
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017552060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511613A (ja
JP2018511613A5 (enExample
Inventor
チンホワ ファン,ペーター
チンホワ ファン,ペーター
カハラマン,メフメット
ヘレン スリー,デボラ
ヘレン スリー,デボラ
デュアン バンカー,ケビン
デュアン バンカー,ケビン
ダニエル ホプキンス,チャド
ダニエル ホプキンス,チャド
ロバート ピンチマン,ジョセフ
ロバート ピンチマン,ジョセフ
エイブラハム,サニー
クメール シット,ラケシュ
クメール シット,ラケシュ
リー セベランス,ダニエル
リー セベランス,ダニエル
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー, リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2018511613A publication Critical patent/JP2018511613A/ja
Publication of JP2018511613A5 publication Critical patent/JP2018511613A5/ja
Application granted granted Critical
Publication of JP6737533B2 publication Critical patent/JP6737533B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017552060A 2015-04-03 2016-03-31 スピロ環式化合物 Expired - Fee Related JP6737533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142946P 2015-04-03 2015-04-03
US62/142,946 2015-04-03
PCT/US2016/025345 WO2016161160A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Publications (3)

Publication Number Publication Date
JP2018511613A JP2018511613A (ja) 2018-04-26
JP2018511613A5 JP2018511613A5 (enExample) 2019-05-09
JP6737533B2 true JP6737533B2 (ja) 2020-08-12

Family

ID=57007413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017552060A Expired - Fee Related JP6737533B2 (ja) 2015-04-03 2016-03-31 スピロ環式化合物

Country Status (25)

Country Link
US (3) US10525036B2 (enExample)
EP (1) EP3277690B1 (enExample)
JP (1) JP6737533B2 (enExample)
KR (1) KR20170132307A (enExample)
CN (1) CN107849053B (enExample)
AU (1) AU2016242940B2 (enExample)
BR (1) BR112017021194A2 (enExample)
CA (1) CA2981055A1 (enExample)
CY (1) CY1123019T1 (enExample)
DK (1) DK3277690T3 (enExample)
ES (1) ES2788160T3 (enExample)
HR (1) HRP20200805T1 (enExample)
HU (1) HUE049481T2 (enExample)
IL (1) IL254662B (enExample)
LT (1) LT3277690T (enExample)
MX (1) MX379622B (enExample)
PL (1) PL3277690T3 (enExample)
PT (1) PT3277690T (enExample)
RS (1) RS60340B1 (enExample)
RU (1) RU2745069C2 (enExample)
SG (1) SG11201707911VA (enExample)
SI (1) SI3277690T1 (enExample)
SM (1) SMT202000279T1 (enExample)
TW (1) TWI705067B (enExample)
WO (1) WO2016161160A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170048588A (ko) * 2014-09-17 2017-05-08 카리라 파마슈티컬스, 아이앤씨. 바이사이클릭 화합물
DK3277690T3 (da) 2015-04-03 2020-05-04 Recurium Ip Holdings Llc Spirocykliske forbindelser
BR112019005305A2 (pt) * 2016-10-05 2019-07-02 Zeno Royalties & Milestones Llc compostos espirocíclicos
WO2018107072A1 (en) 2016-12-08 2018-06-14 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
SG11202007251XA (en) * 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
SG188179A1 (en) 2008-02-21 2013-03-28 Merck Sharp & Dohme Compounds that are erk inhibitors
US20110166124A1 (en) 2008-07-23 2011-07-07 Mccormick Kevin D Tricyclic spirocycle derivatives and methods of use
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2751118B1 (en) 2011-08-29 2016-10-12 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
CN103130775B (zh) * 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
JP6506248B2 (ja) * 2013-03-14 2019-04-24 ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー 二環式鎮痛化合物
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
DK3277690T3 (da) 2015-04-03 2020-05-04 Recurium Ip Holdings Llc Spirocykliske forbindelser
BR112019005305A2 (pt) 2016-10-05 2019-07-02 Zeno Royalties & Milestones Llc compostos espirocíclicos

Also Published As

Publication number Publication date
US20200268714A1 (en) 2020-08-27
LT3277690T (lt) 2020-06-10
DK3277690T3 (da) 2020-05-04
EP3277690B1 (en) 2020-02-26
RS60340B1 (sr) 2020-07-31
MX2017012553A (es) 2018-04-11
WO2016161160A1 (en) 2016-10-06
TW201710261A (zh) 2017-03-16
SMT202000279T1 (it) 2020-07-08
US10493060B2 (en) 2019-12-03
BR112017021194A2 (pt) 2019-01-08
EP3277690A4 (en) 2018-08-22
IL254662B (en) 2021-02-28
US20190201380A1 (en) 2019-07-04
MX379622B (es) 2025-03-11
PL3277690T3 (pl) 2020-08-24
JP2018511613A (ja) 2018-04-26
IL254662A0 (en) 2017-11-30
PT3277690T (pt) 2020-03-24
HUE049481T2 (hu) 2020-09-28
AU2016242940B2 (en) 2020-11-05
RU2017133973A3 (enExample) 2019-07-17
RU2745069C2 (ru) 2021-03-18
SG11201707911VA (en) 2017-10-30
ES2788160T3 (es) 2020-10-20
HRP20200805T1 (hr) 2020-10-16
RU2017133973A (ru) 2019-05-06
CY1123019T1 (el) 2021-10-29
US20180207132A1 (en) 2018-07-26
CN107849053A (zh) 2018-03-27
CN107849053B (zh) 2020-10-30
AU2016242940A1 (en) 2017-10-26
EP3277690A1 (en) 2018-02-07
TWI705067B (zh) 2020-09-21
KR20170132307A (ko) 2017-12-01
SI3277690T1 (sl) 2020-07-31
US10525036B2 (en) 2020-01-07
HK1256671A1 (en) 2019-09-27
CA2981055A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
JP6949952B2 (ja) スピロ環化合物
JP6737533B2 (ja) スピロ環式化合物
JP7112324B2 (ja) Rsv阻害剤としてのベンゾジアゼピン誘導体
US12297190B2 (en) Modulators of STING (stimulator of interferon genes)
TW202241906A (zh) 吲唑化合物
KR20200087132A (ko) Rsv 억제제로서의 병용 약학 제제
KR20210153051A (ko) 매크로사이클릭 화합물
AU2023254182A1 (en) Pyrido[3,2-d]pyrimidines as hpk1 inhibitors
HK1256671B (en) Spirocyclic compounds
WO2025255288A1 (en) Pkc-theta inhibitors, compositions, and methods of use
WO2024155706A1 (en) Tricyclic compounds
NZ751398B2 (en) Spirocyclic compounds

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200616

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200714

R150 Certificate of patent or registration of utility model

Ref document number: 6737533

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees